This HTML5 document contains 170 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n13http://www.rxlist.com/cgi/generic3/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/kegg-drug/
n21http://linked.opendata.cz/resource/drugbank/company/
foafhttp://xmlns.com/foaf/0.1/
n16http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/drugbank/
n28http://linked.opendata.cz/resource/drugbank/dosage/
n15http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/iuphar/
n29http://linked.opendata.cz/resource/drugbank/mixture/
n14http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/guide-to-pharmacology/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/national-drug-code-directory/
n25http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n18http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/chebi/
n5http://linked.opendata.cz/resource/drugbank/patent/
n24http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n26http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n7http://www.drugs.com/cdi/
n10http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/pharmgkb/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/wikipedia/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n17http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/bindingdb/
n11http://linked.opendata.cz/resource/drugbank/drug/DB00334/identifier/kegg-compound/
n27http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00334
rdf:type
n3:Drug
n3:description
Olanzapine is an atypical antipsychotic, approved by the FDA in 1996. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company, whose patent for olanzapine proper ends in 2011.
n3:dosage
n28:271B584D-363D-11E5-9242-09173F13E4C5 n28:271B584E-363D-11E5-9242-09173F13E4C5 n28:271B584F-363D-11E5-9242-09173F13E4C5 n28:271B5850-363D-11E5-9242-09173F13E4C5 n28:271B5851-363D-11E5-9242-09173F13E4C5 n28:271B5852-363D-11E5-9242-09173F13E4C5 n28:271B5853-363D-11E5-9242-09173F13E4C5 n28:271B585C-363D-11E5-9242-09173F13E4C5 n28:271B585D-363D-11E5-9242-09173F13E4C5 n28:271B585E-363D-11E5-9242-09173F13E4C5 n28:271B5854-363D-11E5-9242-09173F13E4C5 n28:271B5855-363D-11E5-9242-09173F13E4C5 n28:271B5856-363D-11E5-9242-09173F13E4C5 n28:271B5857-363D-11E5-9242-09173F13E4C5 n28:271B5858-363D-11E5-9242-09173F13E4C5 n28:271B5859-363D-11E5-9242-09173F13E4C5 n28:271B585A-363D-11E5-9242-09173F13E4C5 n28:271B585B-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# de Haan L, van Amelsvoort T, Rosien K, Linszen D: Weight loss after switching from conventional olanzapine tablets to orally disintegrating olanzapine tablets. Psychopharmacology (Berl). 2004 Sep;175(3):389-90. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15322727 # Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J: Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006 Feb 1;59(3):211-5. Epub 2005 Sep 1. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16139813 # Sepede G, De Berardis D, Gambi F, Campanella D, La Rovere R, D'Amico M, Cicconetti A, Penna L, Peca S, Carano A, Mancini E, Salerno RM, Ferro FM: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol. 2006 Feb;26(1):45-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16415705 # Jakovljevic M, Sagud M, Mihaljevic-Peles A: Olanzapine in the treatment-resistant, combat-related PTSD--a series of case reports. Acta Psychiatr Scand. 2003 May;107(5):394-6; discussion 396. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12752037 # McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A: The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. I. Study rationale and design. Schizophr Res. 2003 May 1;61(1):7-18. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12648731
n3:group
investigational approved
n3:halfLife
21 to 54 hours
n3:indication
For the acute and maintenance treatment of schizophrenia and related psychotic disorders, as well as acute treatment of manic or mixed episodes of bipolar 1 disorder. Intramuscular olanzapine is indicated for the rapid control of agitated patients.
n3:manufacturer
n21:271B5819-363D-11E5-9242-09173F13E4C5
owl:sameAs
n24:DB00334 n25:DB00334
dcterms:title
Olanzapine
adms:identifier
n9:0002-4112-30 n10:PA450688 n11:C07322 n12:D00454 n14:47 n15:47 n16:DB00334 n17:35254 n18:7735 n30:Olanzapine
n3:mechanismOfAction
Olanzapine's antipsychotic activity is likely due to a combination of antagonism at D2 receptors in the mesolimbic pathway and 5HT2A receptors in the frontal cortex. Antagonism at D2 receptors relieves positive symptoms while antagonism at 5HT2A receptors relieves negative symptoms of schizophrenia.
n3:packager
n21:271B5803-363D-11E5-9242-09173F13E4C5 n21:271B5804-363D-11E5-9242-09173F13E4C5 n21:271B5807-363D-11E5-9242-09173F13E4C5 n21:271B5808-363D-11E5-9242-09173F13E4C5 n21:271B5805-363D-11E5-9242-09173F13E4C5 n21:271B5806-363D-11E5-9242-09173F13E4C5 n21:271B580B-363D-11E5-9242-09173F13E4C5 n21:271B580C-363D-11E5-9242-09173F13E4C5 n21:271B5809-363D-11E5-9242-09173F13E4C5 n21:271B580A-363D-11E5-9242-09173F13E4C5 n21:271B580F-363D-11E5-9242-09173F13E4C5 n21:271B5810-363D-11E5-9242-09173F13E4C5 n21:271B580D-363D-11E5-9242-09173F13E4C5 n21:271B580E-363D-11E5-9242-09173F13E4C5 n21:271B5813-363D-11E5-9242-09173F13E4C5 n21:271B5814-363D-11E5-9242-09173F13E4C5 n21:271B5811-363D-11E5-9242-09173F13E4C5 n21:271B5812-363D-11E5-9242-09173F13E4C5 n21:271B5817-363D-11E5-9242-09173F13E4C5 n21:271B5818-363D-11E5-9242-09173F13E4C5 n21:271B5815-363D-11E5-9242-09173F13E4C5 n21:271B5816-363D-11E5-9242-09173F13E4C5
n3:patent
n5:2216372 n5:5229382 n5:6251895 n5:2041113
n3:routeOfElimination
It is eliminated extensively by first pass metabolism, with approximately 40% of the dose metabolized before reaching the systemic circulation. Following a single oral dose of 14C labeled olanzapine, 7% of the dose of olanzapine was recovered in the urine as unchanged drug, indicating that olanzapine is highly metabolized.
n3:synonym
Olanzapin Zyprexa Olanzapine Olanzapina 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine Olanzapinum
n3:toxicity
Symptoms of an overdose include tachycardia, agitation, dysarthria, decreased consciousness and coma. Death has been reported after an acute overdose of 0.45g, but also survival after an acute overdose of 1500g.
n3:volumeOfDistribution
* 1000 L
n19:hasAHFSCode
n20:28-16-08-04
n3:foodInteraction
Avoid alcohol. Take without regard to meals.
n3:mixture
n29:271B5802-363D-11E5-9242-09173F13E4C5 n29:271B5801-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
93%
n3:salt
n3:synthesisReference
Charles Arthur Bunnell, Samuel Dean Larsen, John Richard Nichols, Susan Marie Reutzel, Gregory Alan Stephenson, "Intermediates and process for preparing olanzapine." U.S. Patent US6020487, issued September, 1996.
foaf:page
n7:olanzapine.html n13:symbyax.htm
n3:IUPAC-Name
n4:271B5863-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5869-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5868-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5865-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5866-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5867-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5861-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B587A-363D-11E5-9242-09173F13E4C5 n4:271B585F-363D-11E5-9242-09173F13E4C5 n4:271B5862-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5860-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n27:N05AH03
n3:H-Bond-Acceptor-Count
n4:271B586F-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5870-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B586A-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B586B-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B586D-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B586C-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B586E-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed, with approximately 40% of the dose metabolized before reaching the systemic circulation.
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
132539-06-1
n3:category
n3:clearance
* 12 to 47 L/h
n3:containedIn
n26:271B581A-363D-11E5-9242-09173F13E4C5 n26:271B581B-363D-11E5-9242-09173F13E4C5 n26:271B581E-363D-11E5-9242-09173F13E4C5 n26:271B581F-363D-11E5-9242-09173F13E4C5 n26:271B581C-363D-11E5-9242-09173F13E4C5 n26:271B581D-363D-11E5-9242-09173F13E4C5 n26:271B5822-363D-11E5-9242-09173F13E4C5 n26:271B5823-363D-11E5-9242-09173F13E4C5 n26:271B5820-363D-11E5-9242-09173F13E4C5 n26:271B5821-363D-11E5-9242-09173F13E4C5 n26:271B5826-363D-11E5-9242-09173F13E4C5 n26:271B5827-363D-11E5-9242-09173F13E4C5 n26:271B5824-363D-11E5-9242-09173F13E4C5 n26:271B5825-363D-11E5-9242-09173F13E4C5 n26:271B582A-363D-11E5-9242-09173F13E4C5 n26:271B582B-363D-11E5-9242-09173F13E4C5 n26:271B5828-363D-11E5-9242-09173F13E4C5 n26:271B5829-363D-11E5-9242-09173F13E4C5 n26:271B582E-363D-11E5-9242-09173F13E4C5 n26:271B582F-363D-11E5-9242-09173F13E4C5 n26:271B582C-363D-11E5-9242-09173F13E4C5 n26:271B582D-363D-11E5-9242-09173F13E4C5 n26:271B5832-363D-11E5-9242-09173F13E4C5 n26:271B5833-363D-11E5-9242-09173F13E4C5 n26:271B5830-363D-11E5-9242-09173F13E4C5 n26:271B5831-363D-11E5-9242-09173F13E4C5 n26:271B5836-363D-11E5-9242-09173F13E4C5 n26:271B5837-363D-11E5-9242-09173F13E4C5 n26:271B5834-363D-11E5-9242-09173F13E4C5 n26:271B5835-363D-11E5-9242-09173F13E4C5 n26:271B583A-363D-11E5-9242-09173F13E4C5 n26:271B583B-363D-11E5-9242-09173F13E4C5 n26:271B5838-363D-11E5-9242-09173F13E4C5 n26:271B5839-363D-11E5-9242-09173F13E4C5 n26:271B583E-363D-11E5-9242-09173F13E4C5 n26:271B583F-363D-11E5-9242-09173F13E4C5 n26:271B583C-363D-11E5-9242-09173F13E4C5 n26:271B583D-363D-11E5-9242-09173F13E4C5 n26:271B5842-363D-11E5-9242-09173F13E4C5 n26:271B5843-363D-11E5-9242-09173F13E4C5 n26:271B5840-363D-11E5-9242-09173F13E4C5 n26:271B5841-363D-11E5-9242-09173F13E4C5 n26:271B5846-363D-11E5-9242-09173F13E4C5 n26:271B5847-363D-11E5-9242-09173F13E4C5 n26:271B5844-363D-11E5-9242-09173F13E4C5 n26:271B5845-363D-11E5-9242-09173F13E4C5 n26:271B584A-363D-11E5-9242-09173F13E4C5 n26:271B584B-363D-11E5-9242-09173F13E4C5 n26:271B5848-363D-11E5-9242-09173F13E4C5 n26:271B5849-363D-11E5-9242-09173F13E4C5 n26:271B584C-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5875-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5877-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5878-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5879-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5874-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5873-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5876-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5864-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5871-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5872-363D-11E5-9242-09173F13E4C5